Press release
Castrate-Resistant Prostate Cancer Market is expected to reach $29.79 billion by 2034, growing at a CAGR of 8.7%
Castrate-Resistant Prostate Cancer Market
โ The castrate-resistant prostate cancer market size was valued at USD 12.92 billion in 2024
โ It is anticipated to expand at a CAGR of 8.7% from 2025 to 2034.
โ The market is expected to grow to USD 29.79 billion by 2034.
๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ:
Castrate-resistant prostate cancer (CRPC) is a type of prostate cancer that persists in growing and spreading even when testosterone levels are low (due to androgen deprivation therapy or castration). Generally, prostate cancer depends on testosterone for its growth; however, in CRPC, the cancer cells adjust and become resistant to therapies that reduce testosterone levels. This cancer stage is more aggressive and challenging to treat, frequently necessitating alternative therapies like chemotherapy, immunotherapy, or targeted treatments to control disease advancement.
๐๐๐ญ ๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.polarismarketresearch.com/industry-analysis/castrate-resistant-prostate-cancer-market/request-for-sample
๐๐ซ๐จ๐ฐ๐ญ๐ก ๐ ๐๐๐ญ๐จ๐ซ๐ฌ ๐๐ง๐ ๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ:
The increasing incidence of prostate cancer globally is resulting in more patients experiencing castrate-resistant prostate cancer (CRPC). In this situation, the cancer persists in growing despite therapies that reduce testosterone levels. This expanding patient demographic demands more advanced therapies. Moreover, the global aging population acts as a key factor in driving the growth of the castrate-resistant prostate cancer market. The larger percentage of men joining the geriatric age group is closely linked to a rise in prostate cancer cases and advancement to castrate-resistant stages, heightening the need for advanced CRPC treatment options.
๐๐๐ฒ ๐๐๐ซ๐ญ๐ข๐๐ข๐ฉ๐๐ง๐ญ๐ฌ:
Top companies in the worldwide market focus on strategic acquisitions to boost their research and development capabilities and secure a competitive advantage, enabling them to offer consumers innovative products. Some of the major players participating in the castrate-resistant prostate cancer market are:
โข Sanofi S.A.
โข Johnson & Johnson
โข Pfizer, Inc.
โข Bayer AG
โข Abbott Laboratories
โข GlaxoSmithKline PLC
โข Northwest Biotherapeutics, Inc.
โข Active Biotech AB
๐๐๐ฌ๐ญ๐ซ๐๐ญ๐-๐๐๐ฌ๐ข๐ฌ๐ญ๐๐ง๐ญ ๐๐ซ๐จ๐ฌ๐ญ๐๐ญ๐ ๐๐๐ง๐๐๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ
โข In terms of therapy, in 2024, the hormonal therapy segment accounted for the largest share of the castrate-resistant prostate cancer market due to its proven effectiveness in slowing disease progression by reducing androgen levels.
โข The immunotherapy segment is expected to witness the highest CAGR during the forecast period due to its ability to harness the body's immune system to specifically target and attack prostate cancer cells, offering a promising and less invasive treatment option.
โข In 2024, North America dominated the castrate-resistant prostate cancer market share due to its advanced healthcare infrastructure and high prevalence of prostate cancer.
๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง:
The market is mainly segmented based on therapy and region. Based on therapy analysis, the hormonal therapy segment accounted for the largest market share in 2024 because of its efficiency in controlling disease advancement and prolonging patient life. Modern hormonal therapies have become standard care because they can more accurately target cancer cells and slow down progression.
By Therapy Outlook (Revenue, USD Billion; 2020-2034)
โข Chemotherapy
โข Hormonal Therapy
โข Immunotherapy
โข Radiotherapy
๐๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ-๐๐ข๐ฌ๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ:
โข North America (U.S., Canada)
โข Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
โข Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
โข Latin America (Brazil, Mexico, Argentina)
โข Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
๐๐จ๐ซ๐ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ญ๐๐ฌ๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ฒ ๐๐จ๐ฅ๐๐ซ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Electronic Skin Patch Market
https://www.polarismarketresearch.com/industry-analysis/electronic-skin-patch-market
Cellular Starting Materials Market
https://www.polarismarketresearch.com/industry-analysis/cellular-starting-materials-market
Veterinary Clinical Trials Market
https://www.polarismarketresearch.com/industry-analysis/veterinary-clinical-trials-market
Europe Veterinary Clinical Trials Market
https://www.polarismarketresearch.com/industry-analysis/europe-veterinary-clinical-trials-market
North America Veterinary Clinical Trials Market
https://www.polarismarketresearch.com/industry-analysis/north-america-veterinary-clinical-trials-market
๐๐จ๐ง๐ญ๐๐๐ญ:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
๐๐๐จ๐ฎ๐ญ ๐๐จ๐ฅ๐๐ซ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก & ๐๐จ๐ง๐ฌ๐ฎ๐ฅ๐ญ๐ข๐ง๐ , ๐๐ง๐:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castrate-Resistant Prostate Cancer Market is expected to reach $29.79 billion by 2034, growing at a CAGR of 8.7% here
News-ID: 3802523 • Views: โฆ
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of โฆ
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. Itโฆ
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 โฆ
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected toโฆ
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin โฆ
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billionโฆ
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 โฆ
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reachโฆ
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P โฆ
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focusโฆ
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre โฆ
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causesโฆ
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat โฆ
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of thisโฆ
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm โฆ
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Menโฆ
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapyโฆ
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro โฆ
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitmentโฆ
